Turnstone biologics announces the passing of chief legal officer p. joseph campisi, jr., esq.

San diego, feb. 20, 2024 (globe newswire) -- turnstone biologics corp. (“turnstone” or the “company”) (nasdaq: tsbx), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (selected til) therapy, today announced with sadness that p. joseph campisi, jr., esq, the company's chief legal officer, passed away on february 1, 2024, following a prolonged battle with cancer.
TSBX Ratings Summary
TSBX Quant Ranking